SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J. J. Ferreira, R. Katzenschlager, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, A. Schapira, A. Berardelli, W. H. Oertel, Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  2. 2
    Santiago Perez-Lloret, María Verónica Rey, Nelly Fabre, Fabienne Ory, Umberto Spampinato, Jean-Michel Senard, Anne Pavy-Le Traon, Jean-Louis Montastruc, Olivier Rascol, Factors related to orthostatic hypotension in Parkinson's disease, Parkinsonism & Related Disorders, 2012, 18, 5, 501

    CrossRef

  3. You have free access to this content3
    Spyridon (Spyros) Papapetropoulos, Patient Diaries As a Clinical Endpoint in Parkinson's Disease Clinical Trials, CNS Neuroscience & Therapeutics, 2012, 18, 5
  4. 4
    L.-S. Li, L.-F. Zheng, J.-D. Xu, T. Ji, H. Guo, X.-F. Li, Y. Li, Y. Zhang, J.-X. Zhu, Entacapone promotes cAMP-dependent colonic Cl secretion in rats, Neurogastroenterology & Motility, 2011, 23, 7
  5. 5
    Mark F. Lew, Monique Somogyi, Kevin McCague, Mickie Welsh, on behalf of the LCE QoL Study Grou, Immediate Versus Delayed Switch From Levodopa/Carbidopa to Levodopa/Carbidopa/Entacapone: Effects on Motor Function and Quality of Life in Patients With Parkinson's Disease With End-of-Dose Wearing Off, International Journal of Neuroscience, 2011, 121, 11, 605

    CrossRef

  6. 6
    Rebecca Stowe, Natalie Ives, Carl E. Clarke, Kelly Handley, Alexandra Furmston, Katherine Deane, J.J. van Hilten, Keith Wheatley, Richard Gray, Meta-analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease, Movement Disorders, 2011, 26, 4
  7. 7
    Kapil D. Sethi, The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease, The Neurologist, 2010, 16, 2, 76

    CrossRef

  8. 8
    Kristiina Haasio, Basic Aspects of Catechol-O-Methyltransferase and the Clinical Applications of its Inhibitors, 2010,

    CrossRef

  9. 9
    Nancy L Diaz, Cheryl H Waters, Current strategies in the treatment of Parkinson’s disease and a personalized approach to management, Expert Review of Neurotherapeutics, 2009, 9, 12, 1781

    CrossRef

  10. 10
    Lauren C Seeberger, Robert A Hauser, Levodopa/carbidopa/entacapone in Parkinson’s disease, Expert Review of Neurotherapeutics, 2009, 9, 7, 929

    CrossRef

  11. 11
    Andrew J. Lees, Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease, CNS Neuroscience & Therapeutics, 2008, 14, 1, 83

    CrossRef

  12. 12
    Andrew J. Lees, Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease, CNS Neuroscience & Therapeutics, 2008, 14, 1
  13. 13
    David J. Brooks, Mika Leinonen, Mikko Kuoppamäki, Helena Nissinen, Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson’s disease, Journal of Neural Transmission, 2008, 115, 6, 843

    CrossRef

  14. 14
    David A Gallagher, Anette Schrag, Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease, CNS Drugs, 2008, 22, 7, 563

    CrossRef

  15. 15
    T. Keränen, M. Tuhkasaari, H. Kuusisto, Long-term retention rate of entacapone in the treatment of Parkinson’s disease, European Journal of Neurology, 2008, 15, 4
  16. 16
    Ariel Gordin, David J. Brooks, Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease, Journal of Neurology, 2007, 254, S4, IV37

    CrossRef

  17. 17
    Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease, Movement Disorders, 2007, 22, 1
  18. 18
    F. Grandas, B. Hernández, Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention, European Journal of Neurology, 2007, 14, 3
  19. 19
    Johan Samanta, Robert A Hauser, Levodopa/carbidopa/entacapone for the treatment of Parkinson's disease, Aging Health, 2006, 2, 2, 209

    CrossRef

  20. 20
    V. Myllylä, T. Haapaniemi, S. Kaakkola, E. Kinnunen, P. Hartikainen, J. Nuutinen, A. Rissanen, A. M. Kuopio, T. Jolma, O. Satomaa, H. Heikkinen, Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study), Acta Neurologica Scandinavica, 2006, 114, 3
  21. 21
    M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol, C. Sampaio, Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society–European Section. Part I: early (uncomplicated) Parkinson's disease, European Journal of Neurology, 2006, 13, 11
  22. 22
    Fabrizio Stocchi, The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerations, Expert Opinion on Pharmacotherapy, 2006, 7, 10, 1399

    CrossRef

  23. 23
    Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, 2006,

    CrossRef

  24. 24
    Leslie J Findley, Andrew Lees, Marjo Apajasalo, Anna Pitkänen, Heidi Turunen, Cost-effectiveness of levodopa/carbidopa/entacapone (Stalevo*) compared to standard care in UK Parkinson's disease patients with wearing-off, Current Medical Research and Opinion, 2005, 21, 7, 1005

    CrossRef

  25. 25
    Christopher G. Goetz, Werner Poewe, Olivier Rascol, Cristina Sampaio, Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004, Movement Disorders, 2005, 20, 5
  26. 26
    Fabrizio Stocchi, Optimising levodopa therapy for the management of Parkinson’s disease, Journal of Neurology, 2005, 252, S4, iv43

    CrossRef

  27. 27
    D.J. Brooks, Y. Agid, K. Eggert, H. Widner, K. &Oslash;stergaard, A. Holopainen, Treatment of End-of-Dose Wearing-Off in Parkinson&rsquo;s Disease: Stalevo<sup>&reg;</sup> (Levodopa/Carbidopa/Entacapone) and Levodopa/DDCI Given in Combination with Comtess<sup>&reg;</sup>/Comtan<sup>&reg;</sup> (Entacapone) Provide Equivalent Improvements in Symptom Control Superior to That of Traditional Levodopa/DDCI Treatment, European Neurology, 2005, 53, 4, 197

    CrossRef

  28. 28
    Stéphane Thobois, Florence Delamarre-Damier, Pascal Derkinderen, Treatment of motor dysfunction in Parkinson's disease: an overview, Clinical Neurology and Neurosurgery, 2005, 107, 4, 269

    CrossRef

  29. 29
    Dee E Silver, Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®), Expert Review of Neurotherapeutics, 2004, 4, 4, 589

    CrossRef

  30. 30
    Sotirios A. Parashos, Catherine L. Wielinski, Jessica A. Kern, Frequency, Reasons, and Risk Factors of Entacapone Discontinuation in Parkinson Disease, Clinical Neuropharmacology, 2004, 27, 3, 119

    CrossRef

  31. 31
    Oscar Gershanik, Murat Emre, Gudrun Bernhard, Dirk Sauer, Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: an international, multicentre, open-label study, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 6, 963

    CrossRef

  32. 32
    Reina Benabou, Cheryl Waters, Hepatotoxic profile of catecholOmethyltranferase inhibitors in Parkinson’s disease, Expert Opinion on Drug Safety, 2003, 2, 3, 263

    CrossRef

  33. 33
    J. P. Larsen, J. Worm-Petersen, Å. Sidén, A. Gordin, K. Reinikainen, M. Leinonen, The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease, European Journal of Neurology, 2003, 10, 2
  34. 34
    Michael Schachter, 2003,

    CrossRef

  35. 35
    Margaret M. Swanberg, Jeffrey L. Cummings, Benefit-Risk Considerations in the Treatment of Dementia with Lewy Bodies, Drug Safety, 2002, 25, 7, 511

    CrossRef

  36. 36
    W. H. Poewe, G. Deuschl, A. Gordin, E.-R. Kultalahti, M. Leinonen, Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study), Acta Neurologica Scandinavica, 2002, 105, 4
  37. 37
    Helena Heikkinen, Anu Varhe, Tarmo Laine, Jaakko Puttonen, Marjo Kela, Seppo Kaakkola, Kari Reinikainen, Entacapone improves the availability of l-dopa in plasma by decreasing its peripheral metabolism independent of l-dopa/carbidopa dose, British Journal of Clinical Pharmacology, 2002, 54, 4
  38. 38
    Cheryl Waters, Claire Henchcliffe, Entacapone in the management of Parkinson’s disease, Expert Opinion on Pharmacotherapy, 2002, 3, 7, 957

    CrossRef

  39. 39
    Alexander Fisher, James Croft-Baker, Michael Davis, Patrick Purcell, Allan J. McLean, Entacapone-Induced Hepatotoxicity and Hepatic Dysfunction, Movement Disorders, 2002, 17, 6
  40. 40
    Tim Ibbotson, Karen L. Goa, Management of Parkinson??s Disease, Disease Management & Health Outcomes, 2002, 10, 10, 643

    CrossRef

  41. 41
    J. Lyytinen, S. Kaakkola, A. Gordin, E.-R. Kultalahti, H. Teräväinen, A. Sovijärvi, The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease, Parkinsonism & Related Disorders, 2002, 8, 5, 349

    CrossRef

  42. 42
    Current Awareness, Pharmacoepidemiology and Drug Safety, 2001, 10, 5
  43. 43
    Katherine Deane, Sybille Spieker, Carl E Clarke, Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease, The Cochrane Library,
  44. 44
    W. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa, C. Trenkwalder, Early (Uncomplicated) Parkinson's Disease,
  45. 45
    Rebecca Stowe, Natalie Ives, Carl E Clarke, Katherine Deane, van Hilten, Keith Wheatley, Richard Gray, Kelly Handley, Alex Furmston, Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications, The Cochrane Library,
  46. 46
    Parkinson's Disease, Wiley Handbook of Current and Emerging Drug Therapies,